Loperamide's Effects on Gastric Emptying and Motility

Mechanism of Action and Clinical Evidence

Loperamide is a synthetic μ-opioid receptor agonist that reduces myenteric plexus activity, thereby increasing intestinal transit time and enhancing water reabsorption, as recommended by the European Society for Clinical Nutrition and Metabolism (ESPEN) 1, 2

The ESPEN guidelines recommend loperamide over other opiate drugs because it lacks central opiate effects, is not addictive or sedative, and has a longer duration of action 4, 5
Loperamide is primarily used to reduce stool frequency and improve stool consistency in patients with diarrhea, with a strength of evidence supported by the European Society for Clinical Nutrition and Metabolism (ESPEN) 1, 2

Common side effects include abdominal pain, bloating, nausea, and constipation, which may limit tolerability, as reported in the Gut journal 1, 2
In patients with short bowel syndrome and high-output stomas, loperamide use should be guided by objective measurements of its effect on stool output, according to the Clinical Nutrition journal 4, 5

In patients with short bowel syndrome, high doses of loperamide may be needed (up to 16 tablets/32 mg per day) because the enterohepatic circulation is disrupted in patients without an ileum, as stated in the Clinical Gastroenterology and Hepatology journal 6
For maximum effectiveness in reducing stool output, loperamide should be administered approximately 30 minutes before meals and at bedtime, as recommended by the Clinical Gastroenterology and Hepatology journal 6